Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

Andrew H. Wei; Pau Montesinos; Vladimir Ivanov; Courtney D. DiNardo; Jan Novak; Kamel Laribi; Inho Kim; Don A. Stevens; Walter Fiedler; Maria Pagoni

doi:10.1182/blood.2020004856

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

Identifier:nobleid.org/w1/20260526/DF97EE8E

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/DF97EE8E.svg?ark=w1%2F20260526%2FDF97EE8E)](https://nobleid.org/work/w1/20260526/DF97EE8E)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

Identifier:nobleid.org/w1/20260526/DF97EE8E

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/DF97EE8E.svg?ark=w1%2F20260526%2FDF97EE8E)](https://nobleid.org/work/w1/20260526/DF97EE8E)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work